Story telling component
Options.....
Your cells have a story. We're listening.
 |
Accounting for age |
|
The report is stratified by age - ≤50 years and >50 years. |
 |
Recurrence Score® result |
|
The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample. This number, from 0 to 100, is used to determine distant recurrence risk at 10 years (prognosis) and absolute chemotherapy benefit (prediction). |
 |
Prognosis |
|
Your patient’s individualised 10-year distant recurrence risk (%) with endocrine therapy alone.* *Based on the |
 |
Prediction |
|
The absolute chemotherapy benefit (%) is based on the average benefit of chemotherapy in patients who had the same range of Recurrence Score results.* *Based on the |
 |
Single-Gene Scores |
|
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.
|
 |
Clinical trial description |
|
Contains relevant study details from NSABP B-14, NSABP B-20 or TAILORx. For patients ≤50 years with Recurrence Score results 16-25 this section also contains information on chemotherapy benefit stratified by clinical risk.
|
 |
Additional study information |
|
Displays the patient’s individualised Recurrence Score result in the context of the relevant study data from either TAILORx trial or the NSABP B-20 trial. This example is for a patient over 50 years of age and shows the difference in the 10-year risk of distant recurrence when a patient with a Recurrence Score result of 20 is treated with chemotherapy and endocrine therapy vs endocrine therapy alone.
For all ages and Recurrence Score results 51-100, the data is only available for the group. Therefore, the graph from NSABP B-20 Recurrence Score results 0-50 is shown for information only. |
 |
Data details |
| Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals. |
Story telling component - 2 blocks
|
Accounting for age |
|
The report is stratified by age - ≤50 years and >50 years. |
|
Recurrence Score® result |
|
The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample. This number, from 0 to 100, is used to determine distant recurrence risk at 10 years (prognosis) and absolute chemotherapy benefit (prediction). |
|
Prognosis |
|
Your patient’s individualised 10-year distant recurrence risk (%) with endocrine therapy alone.* *Based on the |
|
Prediction |
|
The absolute chemotherapy benefit (%) is based on the average benefit of chemotherapy in patients who had the same range of Recurrence Score results.* *Based on the |
|
Single-Gene Scores |
|
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.
|
|
Clinical trial description |
|
Contains relevant study details from NSABP B-14, NSABP B-20 or TAILORx. For patients ≤50 years with Recurrence Score results 16-25 this section also contains information on chemotherapy benefit stratified by clinical risk.
|
|
Additional study information |
|
Displays the patient’s individualised Recurrence Score result in the context of the relevant study data from either TAILORx trial or the NSABP B-20 trial. This example is for a patient over 50 years of age and shows the difference in the 10-year risk of distant recurrence when a patient with a Recurrence Score result of 20 is treated with chemotherapy and endocrine therapy vs endocrine therapy alone.
For all ages and Recurrence Score results 51-100, the data is only available for the group. Therefore, the graph from NSABP B-20 Recurrence Score results 0-50 is shown for information only. |
|
Data details |
| Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals. |
2 separate Story telling components stacked
Each Story telling block component only has 1 block defined
Authoring note:
Story telling block component 1
Style - Scroll-based storytelling block/Background color
- Linear gray gradient
Story telling block component 2
Style - Scroll-based storytelling block/Background color
- Neutral 5
|
Accounting for age |
|
The report is stratified by age - ≤50 years and >50 years. |
|
Recurrence Score® result |
|
The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample. This number, from 0 to 100, is used to determine distant recurrence risk at 10 years (prognosis) and absolute chemotherapy benefit (prediction). |
|
Prognosis |
|
Your patient’s individualised 10-year distant recurrence risk (%) with endocrine therapy alone.* *Based on the |
|
Prediction |
|
The absolute chemotherapy benefit (%) is based on the average benefit of chemotherapy in patients who had the same range of Recurrence Score results.* *Based on the |
|
Single-Gene Scores |
|
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.
|
|
Clinical trial description |
|
Contains relevant study details from NSABP B-14, NSABP B-20 or TAILORx. For patients ≤50 years with Recurrence Score results 16-25 this section also contains information on chemotherapy benefit stratified by clinical risk.
|
|
Additional study information |
|
Displays the patient’s individualised Recurrence Score result in the context of the relevant study data from either TAILORx trial or the NSABP B-20 trial. This example is for a patient over 50 years of age and shows the difference in the 10-year risk of distant recurrence when a patient with a Recurrence Score result of 20 is treated with chemotherapy and endocrine therapy vs endocrine therapy alone.
For all ages and Recurrence Score results 51-100, the data is only available for the group. Therefore, the graph from NSABP B-20 Recurrence Score results 0-50 is shown for information only. |
|
Data details |
| Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals. |